Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Division of Cardiac Surgery, Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cardiovasc Revasc Med. 2020 Oct;21(10):1305-1310. doi: 10.1016/j.carrev.2020.03.014. Epub 2020 Mar 7.
Chronic total occlusion (CTO) has been linked to worse survival. While controversial and limited to observational data, successful CTO percutaneous coronary intervention (PCI) has been associated with improved left ventricular (LV) function and mortality. However, the role of CTO PCI prior to transcatheter aortic valve replacement (TAVR) is not clear. We sought to explore the prognostic impact of a pre-TAVR CTO on post-TAVR outcomes.
We retrospectively reviewed 783 consecutive TAVR cases performed at a single tertiary care medical center. Pre-TAVR angiograms were analyzed for the presence of a CTO. At the time of TAVR, 12.6% (n = 99) patients had a CTO. At one-year post-TAVR, there was no significant association between the presence of a CTO and death (14.2% vs 13.1%, p = 0.75), functional status, quality of life, or adverse events. There was also no difference in long-term survival (4.1 years vs 4.1 years, p = 0.55). LV ejection fraction was lower in the CTO group at baseline and one year (p < 0.01).
The presence of a CTO did not have any prognostic impact on mortality, change in LV function, or improvement in functional status and angina scores following TAVR in our cohort of elderly, high-risk patients. CTO before TAVR was associated with decreased ejection fraction at baseline and at one year.
慢性完全闭塞(CTO)与生存率降低有关。虽然成功的 CTO 经皮冠状动脉介入治疗(PCI)与改善左心室(LV)功能和降低死亡率相关,但存在争议,且仅限于观察性数据。然而,经导管主动脉瓣置换术(TAVR)前 CTO PCI 的作用尚不清楚。我们试图探讨 TAVR 前 CTO 对 TAVR 后结局的预后影响。
我们回顾性分析了在一家三级医疗中心进行的 783 例连续 TAVR 病例。在 TAVR 前的血管造影中分析 CTO 的存在。在 TAVR 时,12.6%(n=99)的患者存在 CTO。在 TAVR 后 1 年,CTO 的存在与死亡(14.2%比 13.1%,p=0.75)、功能状态、生活质量或不良事件均无显著相关性。长期生存率也无差异(4.1 年比 4.1 年,p=0.55)。CTO 组在基线和 1 年时的 LV 射血分数均较低(p<0.01)。
在我们的老年高危患者队列中,CTO 的存在对 TAVR 后死亡率、LV 功能变化、功能状态和心绞痛评分的改善没有任何预后影响。TAVR 前 CTO 与基线和 1 年时的射血分数降低相关。